首页|吉西他滨联合奥沙利铂、特瑞普利单抗治疗肝内胆管细胞癌术后合并脾脏转移致血小板减少症1例

吉西他滨联合奥沙利铂、特瑞普利单抗治疗肝内胆管细胞癌术后合并脾脏转移致血小板减少症1例

扫码查看
肝内胆管细胞癌(ICC)是原发性肝癌的一种类型.本文报道了1例ICC术后合并脾脏转移维持化疗的63岁男性患者,该患者联合应用吉西他滨+奥沙利铂+特瑞普利单抗治疗,并在化疗周期内出现白细胞计数和血小板计数减少的情况.给予人粒细胞刺激因子注射液治疗后,白细胞计数增加,血小板计数进一步减少;对症给予重组人血小板生成素注射液治疗,血小板计数增加.对于晚期ICC患者,临床医生可根据专家指南与共识给予患者合适的对症治疗,以延长患者生存期.
A Case Report of Gemcitabine Combined with Oxaliplatin and Toripalimab in the Treatment of Thrombocytopenia Caused by Splenic Metastasis after Surgery for Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma(ICC)is a type of primary liver cancer.This report details a case of splenic metastasis after surgery for ICC in a 63-year-old male patient on maintenance treatment,who was treated with combination therapy with gemcitabine+oxaliplatin+toripalimab and showed decreased white blood cell count and reduced platelet count during the chemotherapy cycle.The patient showed increased white blood cell count and further reduced platelet count in response to treatment with recombinant human granulocyte colony-stimulating factor injection,and showed increased platelet count after symptomatic treatment with recombinant human thrombopoietin injection.For patients with advanced ICC,clinicians may provide appropriate symptomatic treatment according to expert guidelines and consensus,so as to prolong the survival time of patients.

intrahepatic cholangiocarcinomagemcitabineoxaliplatintoripalimabthrombocytopenia

刘耀兴、陈利霞、段春霞、陈晓娟

展开 >

包头医学院第一附属医院肿瘤中心,包头 014010

包头市疾病预防控制中心,包头 014030

肝内胆管细胞癌 吉西他滨 奥沙利铂 特瑞普利单抗 血小板减少

2024

中国合理用药探索
中国执业药师协会

中国合理用药探索

影响因子:0.62
ISSN:2096-3327
年,卷(期):2024.21(5)